Yujiro S. Hata - 12 Jan 2024 Form 4 Insider Report for IDEAYA Biosciences, Inc. (IDYA)

Role
President and CEO, Director
Signature
/s/ Jason Throne, as Attorney-in-Fact for Yujiro Hata
Issuer symbol
IDYA
Transactions as of
12 Jan 2024
Net transactions value
-$2,687,632
Form type
4
Filing time
17 Jan 2024, 17:40:01 UTC
Previous filing
19 Dec 2023
Next filing
05 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDYA Common Stock Options Exercise $52,845 +12,261 +1.8% $4.31* 690,148 12 Jan 2024 Direct
transaction IDYA Common Stock Sale $490,913 -12,261 -1.8% $40.04 677,887 12 Jan 2024 Direct F1, F2
transaction IDYA Common Stock Options Exercise $270,405 +62,739 +9.3% $4.31* 740,626 16 Jan 2024 Direct
transaction IDYA Common Stock Sale $2,519,968 -62,739 -8.5% $40.17 677,887 16 Jan 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDYA Stock Option (right to buy) Options Exercise $0 -12,261 -3.1% $0.000000 387,193 12 Jan 2024 Common Stock 12,261 $4.31 Direct F3
transaction IDYA Stock Option (right to buy) Options Exercise $0 -62,739 -16% $0.000000 324,454 16 Jan 2024 Common Stock 62,739 $4.31 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 11, 2023.
F2 This transaction was executed in multiple trades in prices ranging from $40.00 to $40.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 The shares subject to the option are fully vested and exercisable.
F4 This transaction was executed in multiple trades in prices ranging from $40.00 to $40.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.